Clinical Trial Update: Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer [Phase 2]

View source ↗

Summary

A Phase 2 efficacy study of ZD6474 (vandetanib) for multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ZD6474 (vandetanib) (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED